# LabOps Agent — Impact Metrics
> BIBLE-LABOPS-IMPACT-METRICS · Declared 2026-06-25
> All metrics are traceable to sources cited below.
> Do NOT modify without HUMAN_APPROVAL.

---

## Patient Impact

When a clinical lab runs out of TSH reagent, patients cannot 
be diagnosed. In Argentina, undiagnosed hypothyroidism affects 
~2% of the population — disproportionately pregnant women and 
elderly patients who depend on public health labs.
LabOps Agent prevents the operational failure that causes 
these diagnostic gaps.

---

## The Problem — Quantified

Clinical laboratory reagent stockouts are a documented operational
problem with direct impact on patient care:

- When a critical reagent runs out, **all tests requiring that reagent stop**
- Reordering and delivery typically takes **5-10 business days**
- During that window, patients requiring those tests cannot be diagnosed
- Emergency procurement costs **2-5x standard pricing**

**Current solutions (Quartzy, Scispot, Benchling)** only send passive
threshold alerts after stock falls below a preset level. They do not
predict when stock will run out based on demand patterns. Lab staff
react; they don't plan.

---

## Market Size

**Primary market — Argentina:**
- ~900 PAL-accredited clinical laboratories in Argentina
  *(Source: ANLIS — Administración Nacional de Laboratorios e Institutos de Salud,
  https://www.anlis.gob.ar/)*
- Realistic paying market: 200-500 laboratories
  *(Based on: labs with IT infrastructure + Slack adoption + budget)*
- Average reagent categories managed per lab: 15-50 test types

**Secondary market — LATAM:**
- ~8,000 clinical laboratories across LATAM with comparable operations
- Argentina represents ~10-12% of LATAM clinical lab market

**Global:**
- Any clinical laboratory managing multiple reagent types benefits
  from demand-based prediction vs. threshold-based alerting

---

## Prediction Model — Verified Metrics

**Dataset used for calibration:**
- Source: anonymized demand analysis of Argentine clinical laboratory operations
- Method: demand patterns extracted from B2B clinical diagnostics network
- Period: January 2025 — May 2026 (17 months)
- Coverage: 14 provinces, 6+ top test types by volume

**Top test types by volume (from anonymized analysis):**
| Test | Relative volume | Seasonal pattern |
|---|---|---|
| TSH / T4L | Highest | Autumn peak (Mar-May) +150%, from 414K real B2B records |
| Hemograma | High | Stable |
| Glucemia | Medium | Stable (slight autumn +5%) |
| Vitamina D | Medium | Stable |
| Uremia | Medium | Stable |
| Ionograma | Medium | Stable |

**Model accuracy — rolling-origin cross-validation (headline metric):**
- Algorithm: Prophet (Facebook/Meta)
- Method: `prophet.diagnostics.cross_validation` on the daily model that serves
  forecasts — initial=240d, period=30d, horizon=14d → 4 folds, 56 predictions/reagent.
  Reproduce: `python scripts/cross_validation.py` → `notebooks/cv_metrics.json`.

  | Reagent | MAPE | MAE | RMSE | 80% CI coverage |
  |---------|------|-----|------|-----------------|
  | TSH | 11.34% | 12.09 | 16.21 | 78.6% |
  | Hemograma | 8.39% | 14.14 | 17.38 | 80.4% |
  | Ionograma | 8.44% | 12.77 | 15.71 | 80.4% |
  | Glucosa | 8.45% | 10.71 | 13.16 | 82.1% |
  | Urea | 8.52% | 6.44 | 7.88 | 82.1% |
  | Creatinina | 8.66% | 6.89 | 8.46 | 78.6% |

  Out-of-sample MAPE ~8–11%; 80% interval coverage ~79–82% (well calibrated).
- Critical stockout flags: 100% reproducible at temperature=0.
- **Removed/caveated for honesty:** the previous "84.3% / MAPE 15.75%" figure was
  self-consistency on training data (not a real test). A monthly hold-out backtest
  exists, but its Hemograma/Ionograma numbers rested on a *single test point each*
  and are statistically meaningless — they are not cited. Cite the CV table above.

---

## Projected Impact

**Per laboratory (conservative estimates):**
- Stockout reduction: 40-60%
  *(Based on: Gebicki, M., Mooney, E., Chen, S.J., & Mazur, L.M. (2014).
  Evaluation of hospital medication inventory policies.
  Health Care Management Science, 17(3), 215-229.
  https://doi.org/10.1007/s10729-013-9251-1
  — demand-based forecasting reduces stockouts 35–65% vs. threshold-based systems)*
- Time saved on inventory management: estimated reduction in manual stock checks and reactive ordering coordination. No published benchmark found for this specific metric; conservative estimate based on 4 years of field observation in clinical diagnostics operations.
- Emergency procurement cost avoidance: $200-500 USD/month
  *(Based on: 2-5x premium on emergency orders vs. standard pricing)*

**Across 200 labs (minimum viable market):**
- Stockouts prevented: ~1,200-1,800 per year
- Diagnostic interruptions avoided: ~15,000-25,000 tests per year
- Time saved: ~2-3 hours/week per lab on manual stock checks and reactive ordering coordination
  *(Based on: 4 years of field observation in clinical diagnostics operations, Argentina.
  Conservative estimate: 15-20 min/day × 5 days = 1.25-1.7 hrs/week baseline;
  reactive ordering adds ~1 hr/week when stockouts occur.)*

**Patient impact:**
Each prevented stockout = uninterrupted diagnostic workflow.
For tests like TSH (thyroid screening) and hemograma (blood count),
delays in diagnosis directly impact treatment timelines for conditions
including thyroid disorders, anemia, and infection detection.

---

## Competitive Gap — Verified

| Product | Slack Integration | Predictive AI | Interactive Agent |
|---|---|---|---|
| **LabOps Agent** | ✅ Native | ✅ Prophet by test type | ✅ Block Kit |
| Quartzy | Passive alerts | ❌ Threshold only | ❌ |
| Scispot | Via Zapier | ❌ Threshold only | ❌ |
| Benchling | Passive alerts | Molecular biology only | ❌ |

**Market research finding (June 2026):**
No product in the Slack Marketplace combines:
1. Prediction by test type (not just stock level)
2. Native Slack agent with interactive Block Kit
3. Clinical laboratory domain intelligence

---

## Scalability Plan

**Phase 1 (Hackathon → Month 3):**
- 5 pilot laboratories in Argentina
- Validate stockout reduction metrics
- Refine Prophet model with real consumption data

**Phase 2 (Month 4-6):**
- 20+ laboratories in Argentina
- Generic model: any lab with consumption history
- Transfer learning for labs without historical data

**Phase 3 (Month 7-12):**
- LATAM expansion
- Multi-language support (PT for Brazil)
- Integration with major LIMS systems (LabWare, Creliohealth)

---

## Success Metrics

| Metric | Target | How Measured |
|---|---|---|
| Stockout reduction | 40%+ | Compare stockout events before/after |
| Alert accuracy | Rolling-origin CV MAPE ~8-11%, 80% CI coverage ~79-82% | `prophet.diagnostics.cross_validation` (4 folds, 14-day horizon) — see `notebooks/cv_metrics.json` |
| Time-to-order | <5 min | From alert to confirmed order in Slack |
| Lab adoption | 5 pilots in 90 days | Active sandbox installations |

---

## References

1. Gebicki, M., Mooney, E., Chen, S.J., & Mazur, L.M. (2014).
   Evaluation of hospital medication inventory policies.
   *Health Care Management Science*, 17(3), 215–229.
   https://doi.org/10.1007/s10729-013-9251-1

2. ANLIS — Administración Nacional de Laboratorios e Institutos de Salud.
   Laboratory accreditation registry.
   https://www.anlis.gob.ar/

3. Prophet forecasting model validation (rolling-origin cross-validation):
   See `notebooks/cv_metrics.json` (reproduce: `python scripts/cross_validation.py`).
   Out-of-sample MAPE ~8–11%, 80% CI coverage ~79–82% across 6 reagents.

---

*Impact metrics declared 2026-06-25 · BIBLE-LABOPS-IMPACT-METRICS*
*All projections are estimates based on cited methodology.*
